STOCK TITAN

Millennium-linked firms report ~5.8% holdings in Jasper Therapeutics (JSPR)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. reported Schedule 13G filings showing shared voting and dispositive power by several Millennium-related entities and an affiliate. Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,624,076 shares (5.8%).

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report shared voting and dispositive power over 1,629,013 shares (5.8% each). The filings include a Joint Filing Agreement dated 02/24/2026.

Positive

  • None.

Negative

  • None.

Insights

Large hedge fund entities report significant shared stakes around 5.8% each in Jasper Therapeutics.

The filings list Integrated Core Strategies (US) LLC with shared voting and dispositive power over 1,624,076 shares (5.8%). Several Millennium-related entities and Israel A. Englander each report shared voting and dispositive power over 1,629,013 shares (5.8%).

The filings state these holdings are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers; a 02/24/2026 Joint Filing Agreement is attached. Timing and any trading intent are not disclosed in the excerpt.

The schedule is a regulatory disclosure of group beneficial ownership, not an announcement of transactions.

The cover entries show shared voting and shared dispositive power figures for each filer; Item 4 clarifies holdings are reported via control relationships. The Joint Filing Agreement identifies coordinated reporting among the filers as of 02/24/2026.

These disclosures may affect ownership concentration metrics; subsequent filings would be required to show any changes or transactions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/24/2026
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/24/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/24/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:02/24/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 24, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake does Integrated Core Strategies report in JSPR?

Integrated Core Strategies reports shared voting and dispositive power over 1,624,076 shares, representing 5.8% of the class as shown in the filing dated 02/24/2026. The figure is reported as shared, not sole, authority.

How many shares do Millennium Management entities report owning in JSPR?

Millennium Management LLC and Millennium Group Management LLC each report shared voting and dispositive power over 1,629,013 shares, equal to 5.8% of the class per their Schedule 13G entries dated 02/24/2026. Ownership is reported as shared control.

Does Israel A. Englander report ownership in Jasper Therapeutics (JSPR)?

Yes. Israel A. Englander reports shared voting and dispositive power over 1,629,013 shares, representing 5.8% of the class in the Schedule 13G filing executed 02/24/2026. The filing describes control relationships with Millennium entities.

What formal agreement accompanies these Schedule 13G filings?

The filers attached a Joint Filing Agreement dated 02/24/2026, executed by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander to coordinate their Schedule 13G reporting.

Do these Schedule 13G entries indicate any trading activity?

No trading activity is disclosed in the excerpt. The filing reports beneficial ownership figures and shared voting/dispositive power as of the cover pages and includes the joint filing agreement dated 02/24/2026; it does not state transactions or intent.
Jasper Therapeutics Inc

NASDAQ:JSPR

JSPR Rankings

JSPR Latest News

JSPR Latest SEC Filings

JSPR Stock Data

38.34M
27.69M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
REDWOOD CITY